The first subject of the study is administered with defibrotide by the medical team from National University Corporation Hamamatsu University School of Medicine (HSUM), Fukushima Medical University.
The study is designed to assess the safety and pharmacokinetic profile of Defibrotide in healthy adults.
Gentium is providing defibrotide in addition to technical support to HSUM.